Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling reportBudget impact model

Cost assumptions

18 evidence topics · 17 sources

Budget impact model of cretostimogene grenadenorepvec: cost assumptions

No evidence found.

Cretostimogene grenadenorepvec price

No evidence found.

Gemcitabine intravesical system wholesale acquisition cost

No evidence found.

Medicare Part B payment limits for comparator agents, fourth quarter of 2026
HCPCS code and productShort descriptionHCPCS code dosagePayment limit (USD)Coinsurance percentage
J9029 nadofaragene firadenovec (Adstiladrin)“Instill adstiladrin, tx dose”“PER THERAPEUTIC DOSE”“65200.563”“20.000”
J9028 nogapendekin alfa inbakicept (Anktiva)“Inj, nogapendekin pmln, 1mcg”“1 MCG”“94.139”“20.000”
J9183 gemcitabine intravesical system (Inlexzo)“Gemcitabine intravesical sys”“225 MG”“73054.053”“20.000”
J9271 pembrolizumab (Keytruda)“Inj pembrolizumab”“1 MG”“62.253”“20.000”
J9030 BCG live intravesical“Bcg live intravesical 1mg”“1 MG”“3.532”“20.000”
J9357 valrubicin“Valrubicin injection”“200 MG”“1230.664”“20.000”
J9201 gemcitabine“In gemcitabine hcl nos 200mg”“200 MG”“2.734”“20.000”
J9171 docetaxel“Docetaxel injection”“1 MG”“0.471”“20.000”
J9280 mitomycin“Mitomycin injection”“5 MG”“34.838”“20.000”
Three-month Medicare costs in a published cost-effectiveness model, 2024
Item3 month cost (USD)Range
Radical cystectomy without complications“15850”View highlighted excerpt for this quote“14439–16472”View highlighted excerpt for this quote
Radical cystectomy with major complications“37330”View highlighted excerpt for this quote“36275–37952”View highlighted excerpt for this quote
Pembrolizumab, 200 mg every 3 weeks“46356”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Gemcitabine-docetaxel induction“828”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Gemcitabine-docetaxel maintenance“414”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Nadofaragene, 75 mL every 3 months“63594”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Nogapendekin alfa inbakicept-BCG induction“216189”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Nogapendekin alfa inbakicept-BCG maintenance“108095”View highlighted excerpt for this quote“0–250,000”View highlighted excerpt for this quote
Recurrence, initial cost (TURBT, office visit)“3779”View highlighted excerpt for this quote“2070–5539”View highlighted excerpt for this quote
Surveillance on bladder-sparing therapy“3638 per year”View highlighted excerpt for this quote“3384–7284”View highlighted excerpt for this quote